摘要
目的探讨利妥昔单抗治疗自身免疫性溶血性贫血的有效性和安全性。方法2例难治性自身免疫性溶血性贫血患者,给予利妥昔单抗治疗(375mg/m2,静脉点滴,1次/周,2～4次)。结果2例患者溶血均得到控制,血象恢复,分别随访1年半和1年病情仍稳定。结论利妥昔单抗治疗自身免疫性溶血性贫血是安全、有效的,特别是并发于慢性淋巴细胞白血病的AIHA患者,可作为首选治疗。
Objective： To investigate the effect and security of Rituximab on refractory autoimmune hemolytic anemia（AIHA）. Methods： Two patients with refractory AIHA were treated with Rituximab（375 mg/m^2 once a week, two to four times）. Results： Hemolysis of two refractory patients were controlled by Rituximab and hemoglobin recovered to normal. Followed up for 1.5 and 1 year respectively, they all remained stable. Conclusion： Rituximab may be a second-line treatment for AIHA patients who were refractory to immunosuppressive therapy and the treatment is safe and efficient. Moreover Rituximab can be used as first-line treatment of patients with AIHA secondary to chronic lymphocytic leukemia.
出处
《井冈山大学学报（自然科学版）》
2010年第2期83-85,共3页
Journal of Jinggangshan University (Natural Science)
